The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Power List / 2026 / Power List / Soufiane Z. Azdad

Soufiane Z. Azdad

Pathologist, Inventor, CEO, and Co-founder of Algoscope, France.

  • Q&A

About Soufiane Z. Azdad

What gaps in technology/training/processes concern you most, and how are you addressing them via innovation?

The past 18 months have been eventful in the pharmaceutical industry, which has invested significantly in AI through high-profile, costly acquisitions. This has focused almost entirely on diagnostics and hidden patterns. It's exciting, but it will take years of regulation, clinical validation, and building trust before it reaches its full potential without human supervision, ultimately fulfilling a promise we’ve been hearing for nearly 10 years.

This news highlights a structural problem and a matter of priorities.

In the laboratory, in addition to this unequal distribution of technology and capital, there is pressure on staff, a global shortage of technical and medical personnel that makes any bottleneck problematic. Yet our workflow contains several of them, especially in the preanalytical phase.

What needs to change is the order in which our industry is moving forward. We are trying to automate the most complex and critical decision – the diagnosis – before we have automated the simplest step, which is nonetheless the most error-prone: ensuring that the correct specimen, properly identified and traceable, is transported from the patient to the pathologist.

We cannot entrust the most difficult decision to a “black box” when the data feeding it still comes from a manual, inconsistent, and inadequately documented process.

We need to reverse this approach: first standardize and digitize the workflow, then build layers of intelligence on a solid, reliable, and trustworthy foundation.

Because even with the best scanner on the market and the best foundation models with billions of parameters, they’re useless if a specimen is reversed, lost, or contaminated. And we’ll still spend hours trying to “correct errors” that are sometimes irreversible.

The practical benefit of AI and digital technology should be to reduce errors and improve the traceability and reproducibility of procedures.

For a procedure as important as the macroscopic examination of surgical specimens, we should no longer be left to rely solely on (as the old-timers used to say): a ruler, a scalpel, our dexterity, our general knowledge, and our intuition.

AI can already provide immediate and measurable benefits by finally helping humans catch their breath and having it verify numbers and names on their behalf, automate visual documentation and the description of manual dissection procedures, and, in a sense, "enhance their hands” by guiding them to the location of lesions and the precise measurement of margins.

As a pathologist, I drive this change forward not through rhetoric, but through evidence. The preanalytical solution envisioned by the dreamy resident I once was has come to life – now CE-marked and deployed in several countries – demonstrating that it delivers immediate value without waiting for years of regulatory validation. My approach is to demonstrate concretely that this method works in the real world, until it naturally establishes itself as the new standard. The resulting improvement in quality has a positive ripple effect on the quality of tissue samples and diagnoses, as well as on working conditions.

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Explore Pathology Infectious Disease

The Viral Frontier

January 23, 2024

1 min read

Explore Pathology Genetics and epigenetics

Breathing New Life into Diagnostics

January 22, 2024

6 min read

Explore Pathology Analytical science

Opening a Window into Brain Trauma

January 18, 2024

4 min read

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.